Sareum Holdings PLC Director's Dealing (4654L)
06 Septiembre 2023 - 1:00AM
UK Regulatory
TIDMSAR
RNS Number : 4654L
Sareum Holdings PLC
06 September 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Director's Dealing
Cambridge, UK, 05 September 2023 - Sareum Holdings plc (AIM:
SAR), a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, announces that Dr
Stephen Parker, Non-Executive Chairman, purchased 12,500 ordinary
shares of 0.0125 pence each in the Company ("Ordinary Shares") at
an average price of 80 pence per share on 5 September 2023.
In addition, persons connected with Dr Parker are interested in
a further 25,680 Ordinary Shares in the Company, over which
Ordinary Shares Dr Parker has voting rights discretion.
Therefore, following the transaction, Dr Parker has direct and
indirect interests in an aggregate 116,160 Ordinary Shares in the
Company, representing approximately 0.16 per cent. of the Company's
currently issued share capital.
The notification below, which has been made in accordance with
the requirements of the Market Abuse Regulation, provides further
details.
PDMR Notification Form :
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Stephen Parker
--------------------------------------- -----------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------
a) Position/status Non-Executive Chairman
--------------------------------------- -----------------------------------------
b) Initial notification/amendment Initial notification
--------------------------------------- -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------
a) Name Sareum Holdings plc
--------------------------------------- -----------------------------------------
b) LEI 213800PKERN2DY8FFM72
--------------------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
----------------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 0.0125 pence
instrument, type of instrument each in the share capital of
Sareum Holdings plc
---------------------------------------- ----------------------------------------
Identification code GB00B02RFS12
---------------------------------------- ----------------------------------------
b) Nature of the transaction Purchase of shares
---------------------------------------- ----------------------------------------
c) Price(s) and volume(s)
---------------------------------------- ----------------------------------------
Price(s) Volume(s)
---------------------------------------- ----- ----------- ---------- --------
GBP0.80 12,500
---------------------------------------- --------------------------- ---------- --------
d) Aggregated information
---------------------------------------- ------------------------------ --------
12,500 ordinary shares
* Aggregated volume
---------------------------------------- ---------------------------------------- --------
80 pence per share
* Weighted Average Price
---------------------------------------- ---------------------------------------- --------
e) Date of the transaction 5 September 2023
---------------------------------------- ------------------------------ --------
f) Place of the transaction London Stock Exchange
(AIM)
---------------------------------------- ------------------------------ --------
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014, which is part of UK law by virtue of
the European Union (Withdrawal) Act 2018.
- Ends -
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Lauren Williams, Head of Investor Relations ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel / Patrick Birkholm 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce 020 3764 2341
Consilium Strategic Communications (Financial
PR)
Jessica Hodgson / Davide Salvi / Stella
Lempidaki 020 3709 5700
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology
company developing next generation kinase inhibitors for autoimmune
disease and cancer.
The Company is focused on developing next generation small
molecules which modify the activity of the JAK kinase family and
have best-in-class potential. Its lead candidate, SDC-1801,
simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential
treatment for a range of autoimmune diseases and has entered Phase
1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1
inhibitor which it originally developed in collaboration with
several Cancer Research UK-related organisations. SRA737 has shown
promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a
potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on
the AIM market of the London Stock Exchange, trading under the
ticker SAR. For further information, please visit the Company's
website at www.sareum.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHZZGGLKKRGFZM
(END) Dow Jones Newswires
September 06, 2023 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Sareum (LSE:SAR)
Gráfica de Acción Histórica
De May 2023 a May 2024
